Introduction:
Oil fill vs suspension softgels is a fill-feasibility question: after you have an active and a target dose, should the fill be a lipid solution, a designed suspension, or another dosage form? A softgel manufacturer has to name that path before the die is frozen.
For this page, “oil solution” means a lipid-based fill in which the active is molecularly dissolved. The carrier may contain mixed lipids or other scoped lipid-compatible components. An oil-solution softgel may use a mixed lipid system; “oil-filled” describes the dosage-form route, not a requirement for a single carrier oil. Searchers often say oil-filled softgel; that industry phrase still has to match this technical boundary.
Quick answer: If the active dissolves at the required concentration, evaluate an oil solution. If it does not dissolve but can remain uniformly dispersed at commercial loading, evaluate a suspension. If neither condition can be maintained through encapsulation, change the formula or dosage form.
Key takeaways
- Softgel feasibility is a concentration-and-process problem, not a dose problem alone.
- Fill-weight scatter is not content uniformity.
- Bench appearance is a screen. Continuous encapsulation still has to be checked.
Buyer Snapshot
Typical starting direction for screening — not a permanent assignment of any ingredient.
Oil-solution candidate
Active state: Dissolved in the lipid fill.
Main question: Can it stay dissolved at the required concentration?
Key variables: Solubility, concentration, viscosity, chemical/pack stability.
Manufacturing concern: Metering, seam, oxidation.
Next step: Fill trial on a production-relevant die.
Suspension candidate
Active state: Undissolved particles in a lipid carrier.
Main question: Can it stay uniformly dispersed through encapsulation?
Key variables: Particle size, solids loading, density vs carrier, sedimentation, viscosity.
Manufacturing concern: Agitation, hold time, nozzle, assay vs weight.
Next step: Suspension trial under continuous filling.
Format-change candidate
Active state: Depends.
Main question: Is a standard ribbon still the right platform?
Key variables: Dose, serving size, water/alcohol, carrier incompatibility.
Manufacturing concern: Process and unit-size fit.
Next step: Capsule, tablet, powder, or multi-unit evaluation.
Typical starting points for feasibility screening
These are screening hypotheses. Grade, concentration, and process still decide.
Lipophilic active, readily soluble
Evaluate an oil solution first.
Oil-soluble standardized extract
Evaluate an oil solution first, at the required concentration.
Poorly oil-soluble fine powder
Evaluate a designed suspension — not “powder stirred into oil.”
High-density insoluble powder
Suspension, with a higher screening burden (settling, sampling, nozzle).
High-dose hydrophilic ingredient
Often another dosage form, not a standard oil fill.
High-water or alcohol-heavy liquid
Usually outside a standard ribbon. Needs a different formulation review.
If undissolved particles remain — including a “partially dissolved” brief — it is a suspension file.
Softgel Fill Feasibility: The Decision Path
Cavity volume still follows density and the candidate die. Size screening is covered in how to choose softgel size.
1. Define the active and the required dose
The consumer name is not enough. Specify extract vs purified active, salt / ester / standardized form, particle characteristics if solid, and assay/potency. The same ingredient name can be a solution on one grade and a suspension on another.
Then name the commercial concentration: milligrams of active (and of finished fill) that must sit in one unit or one serving.
Target dose → required concentration → carrier capacity → solids loading → viscosity → encapsulation behavior.
2. Can it dissolve at the required concentration?
Not “does it dissolve in some oil.” Does it dissolve at the concentration the formula requires? Evaluate at that concentration and at relevant processing and storage conditions, not only immediately after mixing. A mix can be soluble at first and still fail after temperature change, hold, or a concentration increase.
If yes, the candidate path is an oil solution. Then check viscosity, oxidation, and ribbon compatibility.
3. If not, can the solid phase remain uniformly dispersed?
Suspension feasibility is four interacting variables: particle-size distribution; particle density vs carrier density; solids loading; viscosity and hold-time behavior. If the solids can be controlled at a defined particle size and loading and the bulk remains dispersible through the vessel, pump, and die, the candidate path is a suspension.
A carrier that dissolves one active may not give the viscosity or density balance another suspension needs.
4. Can that fill run through continuous encapsulation?
Bench feasibility ≠ encapsulation feasibility. A short mix can look uniform and still fail on hold time, metering, seam, or nozzle.
5. When the path fails: change the formula or the format
If neither a solution nor a commercial suspension will run, change carrier, dose, serving count, or dosage form. Do not force a standard ribbon. Two-piece options sit on softgel vs hard capsule.
When an Oil Solution Is the Better Path
Main risks after the path is named: staying in solution at labeled dose through process and storage; viscosity drift; oxidation and pack; odor; gel-mass compatibility.
Self-emulsifying and liposomal systems are not the default on this page. They sit on advanced softgel technologies after a standard fill is feasible.
When a Suspension Softgel Is Feasible
Main risks: sedimentation in the vessel or after filling; nozzle blockage; a bulk that pumps but does not stay uniform.
In a suspension, a capsule can meet the target fill weight while receiving a different proportion of active solids. Fill-weight control and active assay therefore address different risks. The related discussion is in softgel fill weight and seam integrity.
Ask how suspension uniformity is controlled during filling and sampling — not only what the viscosity is.
Why High-Dose Insoluble Actives Challenge Suspension Softgels
High-dose insolubles are often where suspension feasibility breaks down. The problem is not only “too much powder.”
More solids usually means higher viscosity and poorer pumping, a greater sedimentation load, and less carrier to keep the bulk workable.
Dose alone does not determine feasibility. Dose × solubility × solids loading × carrier behavior does. There is no universal milligram ceiling on this page. A suspension can be chemically acceptable and still fail as a commercial softgel fill.
When to Move to Another Dosage Form
The right question is not “Can this ingredient be put into a softgel?” but “Which dosage form gives a commercially workable dose, process and finished product?”
Do not force a standard ribbon when:
- Solids loading exceeds a practical suspension concentration for that carrier and die
- The suspension will not stay uniform through encapsulation
- Particles will not pass the filling system
- The formula needs substantial water or alcohol
- The active is poorly compatible with the lipid carrier
- The finished unit would be commercially unattractive to swallow or pack
Dry botanical powders, high water-activity liquids, and alcohol-heavy bulks usually do not belong in a standard ribbon.
A failed softgel path does not mean the ingredient is unusable. It may mean a hard capsule, tablet, powder, or multi-unit serving is the workable manufacturing route. Format change is a feasibility result, not a branding preference.
What Can Make a Feasible Formula Fail in Production?
A path that looks right on the bench can still fail as a commercial fill. Investigate the symptom, not the ingredient name.
Precipitates after mixing or hold
Look at: Solubility at the intended concentration; temperature; concentration drift.
Settles rapidly
Look at: Particle size; density vs carrier; viscosity; agitation and hold time.
Fill weight consistent, assay varies
Look at: Solids distribution; sampling point and time; agitation continuity.
Nozzle or pump unstable
Look at: Particle size; agglomeration; viscosity at filling temperature.
Beaker OK, continuous run fails
Look at: Residence / hold time; metering; seam under continuous encapsulation.
Fill runs, seam fails or weeps later
Look at: Fill–gel compatibility and process conditions. Diagnosis of leak vs pack sits on why softgels leak.
Needs so much carrier the unit is impractical
Look at: Dose, concentration, serving count, or dosage form — not a larger slogan milligram.
What Changes in Manufacturing
Encapsulation sequence is described in how softgels are made.
Solution path: Homogeneous bulk; controlled holding; metering consistency; viscosity drift; oxidation exposure.
Suspension path: Agitation continuity; residence / hold-time control; particle settling; representative sampling; nozzle passage. A uniform-looking sample is not enough if the sampling point does not represent the bulk during production.
How KS Nutripharma Evaluates Softgel Feasibility
Formulation review typically covers: active specification; target concentration; carrier and path selection (solution vs suspension vs format change); bench screening; a production-relevant encapsulation trial; then fill-weight and assay review as the specification requires.
Production trial — what is actually checked (as the protocol requires): bulk appearance before filling; viscosity at filling temperature; suspension behavior during hold; fill-weight variation; assay variation between sampling points; nozzle and pump behavior; seam integrity; short-term leak or weep; any short-term physical stability the file names.
You do not need to know whether the formula is feasible before contacting the manufacturer. That is part of this review.
What to Send for a Softgel Feasibility Brief
Send what you have:
- Active name and chemical / extract form
- Target active dose per serving and target fill weight
- Intended carrier (or “recommend”)
- Solubility in that carrier, if known
- Particle-size notes, if a powder in oil is in scope
- Bulk density, if available
- Existing sample or prototype
- Desired size or serving-count limit, if any
- Destination market and claim constraints that affect the fill
If you are unsure whether it is a solution, say so. Naming the wrong path wastes the first die screen.
Submit Your Formula for Softgel Feasibility Review
Send the active, target dose, intended carrier, and whether you believe it dissolves.
The initial feasibility review can identify: the likely fill path (solution vs suspension vs format change); key formulation risks; information still needed for trial; whether a softgel trial or a format change should be evaluated. KS Nutripharma then confirms the trial specification and manufacturing route before quoting softgel manufacturing.
Submit your softgel feasibility brief
Related Softgel Manufacturing Guides
- What Are Softgels Made Of?
- Gelatin vs Vegetarian Softgels
- Oil Fill vs Suspension Softgels
- How to Choose Softgel Size
- How Softgels Are Made
- Softgel Fill Weight and Seam Integrity
- Softgel vs Hard Capsule
- How to Read a COA
Only as a designed suspension — or not at all. Dumping powder into oil is not a process.
A lipid fill that carries undissolved particles under a specified particle-size and viscosity file.
No. Weight and assay are different files.
Not as a true solution. If undissolved particles remain, evaluate a suspension. Do not describe it as an oil solution on the RFQ.
They generally need tighter control of particle size, viscosity, agitation, sampling, and fill behavior than a straightforward oil solution. Difficulty still depends on the formulation.
Not by itself. A production-relevant encapsulation trial is still required.
When the load, water, alcohol, or powder physics will not support a standard ribbon. That does not mean the ingredient cannot be manufactured in another format.
FDA dietary-supplement CGMP describes specifications, testing against those specifications, and batch records for finished lots. It does not publish a universal viscosity window, particle-size SOP, or milligram ceiling for nutraceutical softgel fills. Viscosity, sedimentation, and nozzle behavior are established on the formulation and trial — not by copying a public number.
- U.S. Food and Drug Administration. Dietary Supplements.
- U.S. Food and Drug Administration. Current Good Manufacturing Practice in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements, 21 CFR Part 111. Specifications, testing against those specifications, and batch records.
